Authors
Parakkal Deepak, Wooseob Kim, Michael A Paley, Monica Yang, Alexander B Carvidi, Alia A El-Qunni, Alem Haile, Katherine Huang, Baylee Kinnett, Mariel J Liebeskind, Zhuoming Liu, Lily E McMorrow, Diana Paez, Dana C Perantie, Rebecca E Schriefer, Shannon E Sides, Mahima Thapa, Maté Gergely, Suha Abushamma, Michael Klebert, Lynne Mitchell, Darren Nix, Jonathan Graf, Kimberly E Taylor, Salim Chahin, Matthew A Ciorba, Patricia Katz, Mehrdad Matloubian, Jane A O’Halloran, Rachel M Presti, Gregory F Wu, Sean PJ Whelan, William J Buchser, Lianne S Gensler, Mary C Nakamura, Ali H Ellebedy, Alfred HJ Kim
Publication date
2021/4/9
Journal
MedRxiv
Publisher
Cold Spring Harbor Laboratory Preprints
Description
Background:
Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2 vaccination platforms provide robust protection in immunocompetent individuals, the immunogenicity in CID patients on immunosuppression is not well established. Therefore, determining the effectiveness of SARS-CoV-2 vaccines in the setting of immunosuppression is essential to risk-stratify CID patients with impaired protection and provide clinical guidance regarding medication management.
Methods:
We conducted a prospective assessment of mRNA-based vaccine immunogenicity in 133 adults with CIDs and 53 immunocompetent controls. Blood from participants over 18 years of age was collected before initial immunization and 1-2 weeks after the second immunization. Serum anti-SARS-CoV-2 …
Total citations
Scholar articles
P Deepak, W Kim, MA Paley, M Yang, AB Carvidi… - MedRxiv, 2021